Literature DB >> 11325274

The secondary amine/nitric oxide complex ion R(2)N[N(O)NO](-) as nucleophile and leaving group in S9N)Ar reactions.

J E Saavedra1, A Srinivasan, C L Bonifant, J Chu, A P Shanklin, J L Flippen-Anderson, W G Rice, J A Turpin, K M Davies, L K Keefer.   

Abstract

Ions of structure R(2)N[N(O)NO](-) and their alkylation products have seen increasing use as nitric oxide (NO)-generating agents for biomedical research applications. Here we show that such diazeniumdiolate anions can readily displace halide from a variety of electrophilic aza- or nitroaromatic substrates to form O(2)-arylated derivatives of structure R(2)N-N(O)=N-OAr. The site of arylation and the cis arrangement of the oxygens were confirmed by X-ray crystallography. Displacement by various nucleophiles showed R(2)N[N(O)NO](-) to be a reasonably good leaving group, with rate constants for displacement by hydroxide, methoxide, and isopropylamine that were between those of chloride and fluoride in the S(N)Ar reactions we surveyed. The Meisenheimer intermediate could be spectrally observed. These O(2)-aryl diazeniumdiolates proved capable of reacting with the nucleophilic sulfur of the HIV-1 p7 nucleocapsid protein's zinc finger assembly to eject the zinc, disrupting a structural motif critical to viral replication and suggesting possible utility in the drug discovery realm.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11325274     DOI: 10.1021/jo0016529

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  43 in total

1.  Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates.

Authors:  Larry K Keefer
Journal:  For Immunopathol Dis Therap       Date:  2010-07-01

2.  Cellular resistance to a nitric oxide releasing glutathione S-transferase P-activated prodrug, PABA/NO.

Authors:  Steven Hutchens; Yefim Manevich; Lin He; Kenneth D Tew; Danyelle M Townsend
Journal:  Invest New Drugs       Date:  2010-03-16       Impact factor: 3.850

3.  JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.

Authors:  Tanyel Kiziltepe; Kenneth C Anderson; Jeffery L Kutok; Lee Jia; Kenneth M Boucher; Joseph E Saavedra; Larry K Keefer; Paul J Shami
Journal:  J Pharm Pharmacol       Date:  2010-01       Impact factor: 3.765

4.  Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.

Authors:  Anna E Maciag; Rahul S Nandurdikar; Sam Y Hong; Harinath Chakrapani; Bhalchandra Diwan; Nicole L Morris; Paul J Shami; Yih-Horng Shiao; Lucy M Anderson; Larry K Keefer; Joseph E Saavedra
Journal:  J Med Chem       Date:  2011-10-28       Impact factor: 7.446

Review 5.  Nitric oxide and redox mechanisms in the immune response.

Authors:  David A Wink; Harry B Hines; Robert Y S Cheng; Christopher H Switzer; Wilmarie Flores-Santana; Michael P Vitek; Lisa A Ridnour; Carol A Colton
Journal:  J Leukoc Biol       Date:  2011-01-13       Impact factor: 4.962

6.  Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and Double JS-K, through incorporation into PEG-protected nanoparticles.

Authors:  Varun Kumar; Sam Y Hong; Anna E Maciag; Joseph E Saavedra; Douglas H Adamson; Robert K Prud'homme; Larry K Keefer; Harinath Chakrapani
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

7.  Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells.

Authors:  Monika Z Kaczmarek; Ryan J Holland; Stephen A Lavanier; Jami A Troxler; Valentyna I Fesenkova; Charlotte A Hanson; Joan L Cmarik; Joseph E Saavedra; Larry K Keefer; Sandra K Ruscetti
Journal:  Leuk Res       Date:  2013-12-12       Impact factor: 3.156

8.  Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities.

Authors:  Daniela Andrei; Anna E Maciag; Harinath Chakrapani; Michael L Citro; Larry K Keefer; Joseph E Saavedra
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

9.  Structure-Based Design of Anticancer Prodrug PABA/NO.

Authors:  Xinhua Ji; Ajai Pal; Ravi Kalathur; Xun Hu; Yijun Gu; Joseph E Saavedra; Gregory S Buzard; Aloka Srinivasan; Larry K Keefer; Shivendra V Singh
Journal:  Drug Des Devel Ther       Date:  2008       Impact factor: 4.162

10.  JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1.

Authors:  Kornelia Edes; Pamela Cassidy; Paul J Shami; Philip J Moos
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.